Lyell Immunopharma, Inc. revenue for the last year amounted to 130.00 k USD, the most of which — 130.00 k USD — came from its highest performing source at the moment, T-Cell Therapies, the year earlier bringing 84.68 M USD. The greatest contribution to the revenue figure was made by United States — last year it brought Lyell Immunopharma, Inc. 130.00 k USD, and the year before that — 84.68 M USD.